

In the Claims:

1. (Currently Amended) A pharmaceutical composition for the treatment of ~~dermatological disorders~~ psoriatic disorders and contact dermatitis comprising:

a) a therapeutically effective amount of ~~at least one~~ a KPV polypeptide (SEQ ID NO: 1) ~~with a terminal sequence KPV; and~~

b) a therapeutically effective amount of an glucocorticoid anti-inflammatory agent; ~~and, wherein the combination of a KPV polypeptide and glucocorticoid anti-inflammatory agent is effective for treatment of psoriatic disorders and contact dermatitis.~~

~~e) — a carrier.~~

2. (Currently Amended) The pharmaceutical composition of claim 1 wherein ~~the at least one the KPV polypeptide with a terminal sequence KPV is selected from a group consisting of KPV (SEQ. ID. NO. 1), MEHFRWGKPV (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), SYSMEHFRWGKPV (SEQ. ID. NO. 4), or a biologically functional equivalent of any of the foregoing is a KPV monomer or a KPV dimer.~~

3. (Canceled) The pharmaceutical composition of claim 1 wherein the anti-inflammatory agent is a glucocorticoid.

4. (Previously Amended) The pharmaceutical composition of claim ~~3~~ 1 wherein the glucocorticoid is selected from the group consisting of beclomethasone

dipropionate, betamethasone, cortisone, dexamethasone, fluocinonide, hydrocortisone, methyprednisolone, prednisolone, prednisone, and triamcinolone.

5. (Withdrawn) The pharmaceutical composition of claim 1 wherein the anti-inflammatory agent is a non-steroidal anti-inflammatory drug.

6. (Withdrawn) The pharmaceutical composition of claim 5 wherein the non-steroidal anti-inflammatory drug is selected from the group consisting of aspirin, diflusal, fenoprophen calcium, ibuprophen, indomethacin, meclofenamate sodium, naproxen, phenylbutazone, piroxicam, sulindac, and tolmetin sodium.

7. (Previously Presented) The pharmaceutical composition of claim 1 wherein the carrier is selected from the group consisting a cream, an ointment, a balm, a foam, a gel, a stick, and a liquid, and combinations thereof.

8. (Currently Amended) The pharmaceutical composition of claim 7 ~~wherein~~ the further comprising a carrier ~~has its own~~ having medicinal properties selected from the group consisting of emollient properties, analgesic properties, anti-pruritic properties, and soothing properties or combinations thereof.

9. (Canceled) The pharmaceutical composition of claim 8 wherein the medicinal properties are selected from the group consisting of emollient properties, analgesic properties, anti-pruritic properties, and soothing properties or combinations thereof.

10. (Withdrawn) A method of treatment of dermatological disorders comprising:

- a) an administration of a therapeutically effective amount of at least one polypeptide with a terminal sequence KPV;
- b) an administration of a therapeutically effective amount of an anti-inflammatory agent; and
- c) an administration of a carrier.

11. (Withdrawn) The method of treatment in claim 10 wherein the at least one polypeptide with an terminal sequence KPV is selected from a group consisting of KPV (SEQ. ID. NO. 1), MEHFRWGKPV (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), SYSMEHFRWGKPV (SEQ. ID. NO. 4), or a biologically functional equivalent of any of the foregoing.

12. (Withdrawn) The method of treatment in claim 10 wherein the anti-inflammatory agent is a glucocorticoid.

13. (Withdrawn) The method of treatment in claim 12 wherein the glucocorticoid is selected from the group consisting of beclomethasone dipropionate, betamethasone, cortisone, dexamethasone, fluocinonide, hydrocortisone, methyprednisolone, prednisolone, prednisone, and triamcinolone.

14. (Withdrawn) The method of treatment in claim 10 wherein the anti-inflammatory agent is a non-steroidal anti-inflammatory drug.

15. (Withdrawn) The method of treatment in claim 14 wherein the non-steroidal anti-inflammatory drug is selected from the group consisting of aspirin, diflusal, fenoprophen calcium, ibuprophen, indomethacin, meclofenamate sodium, naproxen, phenylbutazone, piroxicam, sulindac, and tolmetin sodium.

16. (Withdrawn) The method of treatment in claim 10 wherein the carrier is selected from the group consisting a cream, an ointment, a balm, an foam, a gel, a stick, and a liquid, and combinations thereof.

17. (Withdrawn) The method of treatment in claim 16 wherein the carrier has its own medicinal properties.

18. (Withdrawn) The method of treatment in claim 17 wherein the medicinal properties are selected from the group consisting of emollient properties, analgesic properties, anti-pruritic properties, and soothing properties or combinations thereof.

19. (Withdrawn) The method of treatment in claim 10 wherein the administration is selected from a group containing topical, nasal, oral, parenteral, and anal.

20. (Canceled) A pharmaceutical composition for the prevention of dermatological disorders comprising:

a) a therapeutically effective amount of at least one polypeptide (SEQ ID NO: 1) with a terminal sequence KPV;

b) a therapeutically effective amount of an anti-inflammatory agent; and,

c) a carrier.

21. (Canceled) The pharmaceutical composition of claim 20 wherein the at least one polypeptide with a terminal sequence KPV is selected from a group consisting of KPV (SEQ. ID. NO. 1), MEHFRWGKPV (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), SYSMEHFRWGKPV (SEQ. ID. NO. 4), or a biologically functional equivalent of any of the foregoing.

22. (Canceled) The pharmaceutical composition of claim 21 wherein the anti-inflammatory agent is a glucocorticoid.

23. (Canceled) The pharmaceutical composition of claim 23 wherein the glucocorticoid is selected from the group consisting of beclomethasone dipropionate, betamethasone, cortisone, dexamethasone, fluocinonide, hydrocortisone, methyprednisolone, prednisolone, prednisone, and triamcinolone.

24. (Canceled) The pharmaceutical composition of claim 21 wherein the anti-inflammatory agent is a non-steroidal anti-inflammatory drug.

25. (Canceled) The pharmaceutical composition of claim 25 wherein the non-steroidal anti-inflammatory drug is selected from the group consisting of aspirin, diflusal, fenoprophen calcium, ibuprophen, indomethacin, meclofenamate sodium, naproxen, phenylbutazone, piroxicam, sulindac, and tolmetin sodium.

26. (Canceled) The pharmaceutical composition of claim 20 wherein the carrier is selected from the group consisting a cream, an ointment, a balm, a foam, a gel, a stick, and a liquid, and combinations thereof.

27. (Canceled) The pharmaceutical composition of claim 2 wherein the carrier has its own medicinal properties selected from the group consisting of emollient properties, analgesic properties, anti-pruritic properties, and soothing properties or combinations thereof.

28. (Canceled) The pharmaceutical composition of claim 28 wherein the medicinal properties are selected from the group consisting of emollient properties, analgesic properties, anti-pruritic properties, and soothing properties or combinations thereof.

29. (Withdrawn) A method of prevention of dermatological disorders comprising:

- a) an administration of a therapeutically effective amount of at least one polypeptide with a terminal sequence KPV;
- b) an administration of a therapeutically effective amount of an anti-inflammatory agent; and
- c) an administration of a carrier.

30. (Withdrawn) The method of treatment in claim 30 wherein the at least one polypeptide with a terminal sequence KPV is selected from the group consisting of KPV

(SEQ. ID. NO. 1), MEHFRWGKPV (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), SYSMEHFRWGKPV (SEQ. ID. NO. 4), or a biologically functional equivalent of any of the foregoing.

31. (Withdrawn) The method of treatment in claim 30 wherein the anti-inflammatory agent is a glucocorticoid.

32. (Withdrawn) The method of treatment in claim 32 wherein the glucocorticoid is selected from the group consisting of beclomethasone dipropionate, betamethasone, cortisone, dexamethasone, fluocinonide, hydrocortisone, methyprednisolone, prednisolone, prednisone, and triamcinolone.

33. (Withdrawn) The method of treatment in claim 30 wherein the anti-inflammatory agent is a non-steroidal anti-inflammatory drug.

34. (Withdrawn) The method of treatment in claim 34 wherein the non-steroidal anti-inflammatory drug is selected from the group consisting of aspirin, diflusal, fenoprophen calcium, ibuprophen, indomethacin, meclofenamate sodium, naproxen, phenylbutazone, piroxicam, sulindac, and tolmetin sodium.

35. (Withdrawn) The method of treatment in claim 30 wherein the carrier is selected from the group consisting a cream, an ointment, a balm, an foam, a gel, a stick, and a liquid, and combinations thereof.

36. (Withdrawn) The method of treatment in claim 36 wherein the carrier has its own medicinal properties.

37. (Withdrawn) The method of treatment in claim 37 wherein the medicinal properties are selected from the group consisting of emollient properties, analgesic properties, anti-pruritic properties, and soothing properties or combinations thereof.

38. (Withdrawn) The method of treatment in claim 30 wherein the administration is selected from a group containing topical, nasal, oral, parenteral, and anal.